| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD223; Lag3; Lymphocyte activating 3; Protein FDC;;LAG 3 |
| WB Predicted band size | Calculated MW: 57 kDa ; Observed MW: 60-80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human LAG 3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于CD223(LAG-3)抗体的参考文献摘要：
---
1. **文献名称**：*LAG-3: A very singular immune checkpoint*
**作者**：Andrews, L.P., et al.
**摘要**：综述LAG-3在T细胞耗竭中的功能及其作为免疫检查点的治疗潜力，重点探讨LAG-3抗体通过阻断T细胞抑制信号增强抗肿瘤免疫应答的机制。
2. **文献名称**：*Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma*
**作者**：Tawbi, H.A., et al.
**摘要**：临床试验表明，联合使用LAG-3抗体Relatlimab与PD-1抗体Nivolumab显著延长晚期黑色素瘤患者的无进展生存期，验证LAG-3作为联合免疫治疗靶点的有效性。
3. **文献名称**：*LAG-3 modulates CD8+ T cell exhaustion and tumor immunity*
**作者**：Woo, S.R., et al.
**摘要**：通过动物模型证明LAG-3抗体可逆转T细胞耗竭状态，增强抗肿瘤活性，并揭示LAG-3与PD-1通路的协同抑制作用，为联合疗法提供理论支持。
---
这些文献涵盖基础机制、临床转化及联合治疗研究，反映LAG-3抗体在肿瘤免疫治疗中的关键作用。
CD223 (LAG-3) antibodies target the Lymphocyte Activation Gene-3 protein, a transmembrane immune checkpoint receptor primarily expressed on activated T cells, natural killer (NK) cells, and regulatory T cells (Tregs). Discovered in the 1990s, LAG-3 modulates immune responses by binding to MHC class II molecules with high affinity, delivering inhibitory signals that dampen T-cell activation, proliferation, and effector functions. This regulatory mechanism helps maintain immune tolerance but is often exploited by tumors to evade immune surveillance.
CD223 antibodies are designed to block LAG-3/MHC-II interactions or disrupt downstream signaling, thereby reversing T-cell exhaustion and enhancing anti-tumor immunity. Preclinical studies highlight their synergy with PD-1/PD-L1 inhibitors, leading to combined checkpoint blockade strategies. In 2022. the FDA approved relatlimab (anti-LAG-3) combined with nivolumab (anti-PD-1) for advanced melanoma, marking a milestone in LAG-3-targeted therapy. Current research explores their efficacy in other cancers, autoimmune diseases, and chronic infections. Challenges include optimizing therapeutic windows and understanding resistance mechanisms. As a promising immunomodulatory tool, CD223 antibodies continue to reshape cancer immunotherapy paradigms.
×
